Antipyrine elimination in saliva after low-dose combined or progestogen-only oral contraceptive steroids

D M Chambers, Gordon C Jefferson, M. Chambers, N. B. Loudon

Research output: Contribution to journalArticle

Abstract

A 'low-dose' combined oral contraceptive steroid (OCS) preparation containing 30 µg ethinyloestradiol and 150 µg levonorgestrel was found to reduce significantly antipyrine clearance in a group of women acting as their own controls. An OCS preparation containing only a progestogen (75 µg norgestrel) did not reduce antipyrine clearance in a second group of women. The evidence suggesting that the oestrogen component of combined OCS preparations could be responsible for the reduction in antipyrine clearance is discussed.

Original languageEnglish
Pages (from-to)229-232
Number of pages4
JournalBritish Journal of Clinical Pharmacology
Volume13
Issue number2
Publication statusPublished - 1982

Fingerprint

Antipyrine
Progestins
Oral Contraceptives
Saliva
Contraceptives, Oral, Combined
Steroids
Norgestrel
Levonorgestrel
Ethinyl Estradiol
Estrogens

Cite this

Chambers, D M ; Jefferson, Gordon C ; Chambers, M. ; Loudon, N. B. / Antipyrine elimination in saliva after low-dose combined or progestogen-only oral contraceptive steroids. In: British Journal of Clinical Pharmacology. 1982 ; Vol. 13, No. 2. pp. 229-232.
@article{47fa96a003e24349bba018c493541ad9,
title = "Antipyrine elimination in saliva after low-dose combined or progestogen-only oral contraceptive steroids",
abstract = "A 'low-dose' combined oral contraceptive steroid (OCS) preparation containing 30 µg ethinyloestradiol and 150 µg levonorgestrel was found to reduce significantly antipyrine clearance in a group of women acting as their own controls. An OCS preparation containing only a progestogen (75 µg norgestrel) did not reduce antipyrine clearance in a second group of women. The evidence suggesting that the oestrogen component of combined OCS preparations could be responsible for the reduction in antipyrine clearance is discussed.",
author = "Chambers, {D M} and Jefferson, {Gordon C} and M. Chambers and Loudon, {N. B.}",
year = "1982",
language = "English",
volume = "13",
pages = "229--232",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "2",

}

Antipyrine elimination in saliva after low-dose combined or progestogen-only oral contraceptive steroids. / Chambers, D M; Jefferson, Gordon C; Chambers, M.; Loudon, N. B.

In: British Journal of Clinical Pharmacology, Vol. 13, No. 2, 1982, p. 229-232.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antipyrine elimination in saliva after low-dose combined or progestogen-only oral contraceptive steroids

AU - Chambers, D M

AU - Jefferson, Gordon C

AU - Chambers, M.

AU - Loudon, N. B.

PY - 1982

Y1 - 1982

N2 - A 'low-dose' combined oral contraceptive steroid (OCS) preparation containing 30 µg ethinyloestradiol and 150 µg levonorgestrel was found to reduce significantly antipyrine clearance in a group of women acting as their own controls. An OCS preparation containing only a progestogen (75 µg norgestrel) did not reduce antipyrine clearance in a second group of women. The evidence suggesting that the oestrogen component of combined OCS preparations could be responsible for the reduction in antipyrine clearance is discussed.

AB - A 'low-dose' combined oral contraceptive steroid (OCS) preparation containing 30 µg ethinyloestradiol and 150 µg levonorgestrel was found to reduce significantly antipyrine clearance in a group of women acting as their own controls. An OCS preparation containing only a progestogen (75 µg norgestrel) did not reduce antipyrine clearance in a second group of women. The evidence suggesting that the oestrogen component of combined OCS preparations could be responsible for the reduction in antipyrine clearance is discussed.

UR - http://www.scopus.com/inward/record.url?scp=0020368424&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 229

EP - 232

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 2

ER -